T
Teresa Klinowska
Researcher at AstraZeneca
Publications - 69
Citations - 4616
Teresa Klinowska is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 23, co-authored 61 publications receiving 3733 citations. Previous affiliations of Teresa Klinowska include University of Manchester.
Papers
More filters
Journal ArticleDOI
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
Erika Hamilton,Mafalda Oliveira,Udai Banerji,Cristina Hernando,Javier Garcia-Corbacho,Anne C Armstrong,Eva Ciruelos,Manish R. Patel,Jason Incorvati,Chris Twelves,Tim Brier,Danielle Carroll,Steven Fox,Teresa Klinowska,Justin P.O. Lindemann,Richard Mather,Rhiannon Maudsley,Sam McGuinness,Andy Sykes,Richard D. Baird +19 more
TL;DR: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader that has shown antitumor efficacy in a range of preclinical models of breast cancer.
Journal ArticleDOI
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Helen Creedon,Laura Gómez-Cuadrado,Žygimantė Tarnauskaitė,Jozef Balla,Marta Canel,Kenneth G. MacLeod,Bryan Serrels,Craig Fraser,Asier Unciti-Broceta,Natasha Tracey,Thierry Le Bihan,Teresa Klinowska,Andrew H. Sims,Adam Byron,Valerie G. Brunton +14 more
TL;DR: It is demonstrated that a subset of these EMT-associated genes is predictive of prognosis within the ERBB2 subtype of human breast cancers, and inhibitors to these kinases may provide additional options for the treatment of HER2-independent resistance in tumors.
Journal ArticleDOI
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
John F.R. Robertson,Abigail Evans,S. Henschen,Cliona C. Kirwan,A Jahan,Laura M. Kenny,J Michael Dixon,Peter Schmid,Ashutosh Kothari,Omar Mohamed,Peter A. Fasching,Kwok-Leung Cheung,Rachel Wuerstlein,Danielle Carroll,Teresa Klinowska,Justin P.O. Lindemann,Alexander MacDonald,Richard Mather,Rhiannon Maudsley,Michele Moschetta,Myria Nikolaou,Martine P. Roudier,Tinnu Sarvotham,Gaia Schiavon,Diansong Zhou,Li Zhou,Nadia Harbeck +26 more
TL;DR: This was the first presurgical study to demonstrate that an oral SERD affects its key biological targets, however, AZD9496 was not superior to fulvestrant at the dose tested.
Journal ArticleDOI
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
Zhaomei Mu,Zhaomei Mu,Teresa Klinowska,Xiaoshen Dong,Emily Foster,Chris Womack,Sandra V. Fernandez,Sandra V. Fernandez,Massimo Cristofanilli,Massimo Cristofanilli +9 more
TL;DR: AZD8931 single agent and in combination with paclitaxel demonstrated signal inhibition and antitumor activity in EGFR-overexpressed and HER2 non-amplified IBC models, suggesting that AZD 8931 may provide a novel therapeutic strategy for the treatment of IBC patients with HER2Non-amPLified tumors.
Journal ArticleDOI
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
James T. Lynch,Urszula M. Polanska,Ursula Hancox,Oona Delpuech,Juliana Maynard,Catherine B. Trigwell,Catherine Anne Eberlein,Carol Lenaghan,Radoslaw Polanski,Alvaro Avivar-Valderas,Marie Cumberbatch,Teresa Klinowska,Susan E. Critchlow,Francisco Cruzalegui,Simon T. Barry +14 more
TL;DR: Combining the PI3Kβ inhibitor AZD8186 and vistusertib has potential to be an effective combination treatment for PTEN-null tumors and in vivo biomarker analysis revealed that the monotherapy and combination treatment consistently reduced similar biomarkers, while combination increased nuclear translocation of the transcription factor FOXO3 and reduction in glucose uptake.